Objectives: To evaluate the impact of using clinical stage assessed by multiparametric magnetic resonance imaging (mpMRI) on the performance of two established nomograms for the prediction of pelvic lymph node involvement (LNI) in patients with prostate cancer.
Patients And Methods: Patients undergoing robot-assisted extended pelvic lymph node dissection (ePLND) from 2015 to 2019 at three teaching hospitals were retrospectively evaluated. Risk of LNI was calculated four times for each patient, using clinical tumour stage (T-stage) assessed by digital rectal examination (DRE) and by mpMRI, in the Memorial Sloan Kettering Cancer Centre (MSKCC; 2018) and Briganti (2012) nomograms. Discrimination (area under the curve [AUC]), calibration, and the net benefit of these four strategies were assessed and compared.
Results: A total of 1062 patients were included, of whom 301 (28%) had histologically proven LNI. Using DRE T-stage resulted in AUCs of 0.71 (95% confidence interval [CI] 0.70-0.72) for the MSKCC and 0.73 (95% CI 0.72-0.74) for the Briganti nomogram. Using mpMRI T-stage, the AUCs were 0.72 (95% CI 0.71-0.73) for the MSKCC and 0.75 (95% CI 0.74-0.76) for the Briganti nomogram. mpMRI T-stage resulted in equivalent calibration compared with DRE T-stage. Combined use of mpMRI T-stage and the Briganti 2012 nomogram was shown to be superior in terms of AUC, calibration, and net benefit. Use of mpMRI T-stage led to increased sensitivity for the detection of LNI for all risk thresholds in both models, countered by a decreased specificity, compared with DRE T-stage.
Conclusion: T-stage as assessed by mpMRI is an appropriate alternative for T-stage assessed by DRE to determine nomogram-based risk of LNI in patients with prostate cancer, and was associated with improved model performance of both the MSKCC 2018 and Briganti 2012 nomograms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bju.15376 | DOI Listing |
Strahlenther Onkol
January 2025
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
Purpose: This study aimed to evaluate the prognostic significance of magnetic resonance imaging (MRI) parameters on biochemical failure-free survival (BFS) in patients diagnosed with intermediate-risk prostate cancer and treated with robotic ultrahypofractionated stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT).
Methods: A retrospective analysis was conducted in patients with intermediate-risk prostate cancer undergoing robotic SBRT delivered in five fractions with a total radiation dose of 35-36.25 Gy.
Fr J Urol
January 2025
Department of Urology, North Hospital, AP-HM, Marseille, France.
Introduction: A significant proportion of newly diagnosed prostate cancer (PCa) cases are slow growing with a low risk of metastatic progression. There is a lack of data concerning the optimal biopsy regimen for improving diagnosis yield in PI-RADS3 lesions. This study aimed to assess the diagnostic value of current biopsy regimens in PI-RADS 3 lesions and identify clinical predictors to improve clinically significant PCa (csPCa) detection.
View Article and Find Full Text PDFProstate
December 2024
Department of Pathology, Houston Methodist Hospital, Houston Methodist Research Institute, Houston, Texas, USA.
Background: Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in the current Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) is considered optional, with primary scoring based on T2-weighted imaging (T2WI) and diffusion weighted imaging (DWI).
View Article and Find Full Text PDFTechnol Cancer Res Treat
December 2024
Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Since the response of patients with rectal cancer (RC) to neoadjuvant therapy is highly variable, there is an urgent need to develop accurate methods to predict the post-treatment T (pT) stage. The purpose of this study was to evaluate the utility of multi-parametric MRI radiomics models and identify the most accurate machine learning (ML) algorithms for predicting pT stage of RC.
Method: This retrospective study analyzed pretreatment clinical features of 171 RC patients who underwent 3 T MRI prior to neoadjuvant therapy and subsequent total mesorectal excision.
BMC Cancer
November 2024
Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Objective: To build and validate a periprostatic fat magnetic resonance imaging (MRI) based radiomics nomogram for prediction of biochemical recurrence-free survival (bRFS) of patients with non-metastatic prostate cancer (PCa) receiving radical prostatectomy (RP).
Methods: A retrospective study was conducted on 356 patients with non-metastatic PCa who underwent preoperative mpMRI followed by RP treatment at our institution. Radiomic features were extracted from both intratumoral region and the periprostatic fat region, which were segmented on images obtained through T2-weighted imaging (T2WI) and apparent-diffusion coefficient (ADC) imaging.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!